Literature DB >> 11936926

Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects.

Thomas J Raife1, Donna J Lager.   

Abstract

OBJECTIVE: To describe 6 patients who developed progressive renal failure and renal thrombotic microangiopathy (TM) not accompanied by the characteristic hematologic disturbances of TM syndromes. PATIENTS AND METHODS: Portions of renal biopsy specimens from each patient were examined by light and electron microscopy for histopathologic evidence of TM. Antecedent clinical events, laboratory evidence of hemolysis and thrombocytopenia, and clinical outcome were documented. Medical records were reviewed and clinical data, including laboratory values, treatment, and outcome, were recorded.
RESULTS: In each case, a slowly progressive uremia evolved after radiation and/or chemotherapy without laboratory evidence of acute hemolysis or thrombocytopenia. Renal biopsy specimens in all cases showed TM and tubulointerstitial scarring, suggesting both acute and chronic renal injury. Two of the 6 patients underwent plasma exchange therapy without improvement of renal function. Three patients treated with angiotensin-converting enzyme inhibitors for coexisting systemic hypertension remained stable or had mild improvement in renal function.
CONCLUSIONS: A small subset of patients treated for malignancy developed slowly evolving uremia associated with renal TM without marked hematologic abnormalities. In the absence of thrombocytopenia and other typical laboratory findings, the diagnosis of renal TM may be overlooked.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936926     DOI: 10.4065/77.4.323

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  2 in total

1.  Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation.

Authors:  Ilya G Glezerman; Kenar D Jhaveri; Thomas H Watson; Alison M Edwards; Esperanza B Papadopoulos; James W Young; Carlos D Flombaum; Ann A Jakubowski
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-12       Impact factor: 5.742

2.  Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.

Authors:  Jung Soo Kim; Jeong-Seon Ryu; Sang Hoon Jeon; Hyun-Jung Kim; Hae-Seong Nam; Jae Hwa Cho; Seung Min Kwak; Hong Lyeol Lee
Journal:  J Int Med Res       Date:  2017-07-21       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.